S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)

Arvinas (ARVN) Stock Price, News & Analysis

$47.30
+1.32 (+2.87%)
(As of 03/1/2024 ET)
Today's Range
$46.66
$51.51
50-Day Range
$36.38
$52.31
52-Week Range
$13.57
$53.08
Volume
1.02 million shs
Average Volume
754,375 shs
Market Capitalization
$3.22 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$59.93

Arvinas MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
26.7% Upside
$59.93 Price Target
Short Interest
Bearish
17.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.26mentions of Arvinas in the last 14 days
Based on 41 Articles This Week
Insider Trading
Selling Shares
$404,489 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.44) to ($5.32) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.14 out of 5 stars

Medical Sector

407th out of 957 stocks

Pharmaceutical Preparations Industry

191st out of 440 stocks


ARVN stock logo

About Arvinas Stock (NASDAQ:ARVN)

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

ARVN Stock Price History

ARVN Stock News Headlines

Arvinas (NASDAQ:ARVN) PT Raised to $59.00 at Wedbush
Bezos and Gates Invest in Search for Tech's Best-Kept Secret
Billionaires who've made their fortunes in tech, are quietly investing in essential yet rare elements known as "The Seeds of Technology". Learn more about this massive rare earth treasure hunt and the very elements making emerging technologies possible.
Ronald Peck Sells 1,699 Shares of Arvinas, Inc. (NASDAQ:ARVN) Stock
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
Piper Sandler Keeps Their Buy Rating on Arvinas Holding Company (ARVN)
Navigating 7 Analyst Ratings For Arvinas
Arvinas: Q4 Earnings Insights
Arvinas Announces Chief Financial Officer Transition
Arvinas Announces Chief Financial Officer Transition
ARVN Mar 2024 60.000 call
ARVN Mar 2024 45.000 put
See More Headlines
Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/01/2024
Next Earnings (Estimated)
5/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ARVN
Fax
N/A
Employees
415
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$59.93
High Stock Price Target
$90.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+30.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
16 Analysts

Profitability

Net Income
$-282,500,000.00
Net Margins
-185.09%
Pretax Margin
-463.57%

Debt

Sales & Book Value

Annual Sales
$78.50 million
Book Value
$9.69 per share

Miscellaneous

Free Float
53,623,000
Market Cap
$3.13 billion
Optionable
Optionable
Beta
1.96
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. John G. Houston Ph.D. (Age 64)
    Chairperson, CEO & President
    Comp: $1.08M
  • Mr. Sean A. Cassidy CPAMr. Sean A. Cassidy CPA (Age 54)
    M.B.A., CFO, Principal Financial Officer & Treasurer
    Comp: $683k
  • Dr. Ian Taylor Ph.D. (Age 61)
    Chief Scientific Officer
    Comp: $692k
  • Dr. Ronald A. Peck M.D. (Age 58)
    Chief Medical Officer
    Comp: $701.63k
  • Mr. David K. Loomis M.B.A. (Age 50)
    VP, Principal Accounting Officer & Chief Accounting Officer
  • Mr. Jeff Boyle
    Vice President of Investor Relations
  • Mr. Jared M. Freedberg J.D. (Age 55)
    General Counsel
  • Dr. Randy Teel Ph.D. (Age 45)
    Senior Vice President of Corporate & Business Development
  • Mr. Steve Weiss (Age 54)
    Senior VP & Chief Human Resources Officer
  • Dr. John A. Grosso Ph.D. (Age 67)
    Senior Vice President of R&D Technical Operations














ARVN Stock Analysis - Frequently Asked Questions

Should I buy or sell Arvinas stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last twelve months. There are currently 2 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ARVN shares.
View ARVN analyst ratings
or view top-rated stocks.

What is Arvinas' stock price target for 2024?

16 brokers have issued 1 year target prices for Arvinas' stock. Their ARVN share price targets range from $20.00 to $90.00. On average, they predict the company's stock price to reach $59.93 in the next twelve months. This suggests a possible upside of 26.7% from the stock's current price.
View analysts price targets for ARVN
or view top-rated stocks among Wall Street analysts.

How have ARVN shares performed in 2024?

Arvinas' stock was trading at $41.16 at the beginning of 2024. Since then, ARVN stock has increased by 14.9% and is now trading at $47.30.
View the best growth stocks for 2024 here
.

Are investors shorting Arvinas?

Arvinas saw a increase in short interest in February. As of February 15th, there was short interest totaling 7,770,000 shares, an increase of 19.5% from the January 31st total of 6,500,000 shares. Based on an average daily volume of 875,900 shares, the days-to-cover ratio is presently 8.9 days. Approximately 17.1% of the shares of the stock are sold short.
View Arvinas' Short Interest
.

When is Arvinas' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our ARVN earnings forecast
.

How were Arvinas' earnings last quarter?

Arvinas, Inc. (NASDAQ:ARVN) posted its quarterly earnings data on Tuesday, February, 27th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.15) by $1.38. The firm had revenue of ($43.10) million for the quarter, compared to the consensus estimate of $38.91 million. Arvinas had a negative net margin of 185.09% and a negative trailing twelve-month return on equity of 70.24%. During the same period last year, the business earned ($1.56) EPS.

What ETFs hold Arvinas' stock?
What other stocks do shareholders of Arvinas own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

When did Arvinas IPO?

(ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

Who are Arvinas' major shareholders?

Arvinas' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.82%), RTW Investments LP (7.66%), Price T Rowe Associates Inc. MD (6.96%), Price T Rowe Associates Inc. MD (6.96%), Avidity Partners Management LP (5.42%) and Bellevue Group AG (4.56%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy and Timothy M Shannon.
View institutional ownership trends
.

How do I buy shares of Arvinas?

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARVN) was last updated on 3/1/2024 by MarketBeat.com Staff